Title:
がんに対するＡ＊０１拘束性ペプチドおよびペプチド組み合わせによる免疫療法
Document Type and Number:
Japanese Patent JP7476174
Kind Code:
B2
Abstract:
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
More Like This:
Inventors:
Schuster, Heiko
Sontag, Anika
Daniel, Kovalewski
Shall, Oliver
Fritche, jens
Weinschenk, Toni
Shin, Harpreet
Song, collet
Sontag, Anika
Daniel, Kovalewski
Shall, Oliver
Fritche, jens
Weinschenk, Toni
Shin, Harpreet
Song, collet
Application Number:
JP2021514549A
Publication Date:
April 30, 2024
Filing Date:
September 18, 2019
Export Citation:
Assignee:
Immatics Biotechnology Gem Beher
International Classes:
C07K7/06; A61K9/08; A61K9/19; A61K38/08; A61K39/00; A61K39/39; A61K39/395; A61P35/00; A61P35/02; A61P37/04; A61P43/00; C07K16/18; C07K16/28; C12N5/10; C12N15/115; C12N15/12; C12N15/13; C12P21/02; C12P21/08; C12Q1/6837; C12Q1/6869
Domestic Patent References:
| JP2018519243A |
Foreign References:
| WO2017202806A1 | ||||
| WO2017097699A1 |
Other References:
YEE, Nelson S.,Cancers,2015年10月23日,Vol. 7, No. 4,pp. 2134-2146,DOI: 10.3990/cancers7040882
がん免疫療法のメカニズム解明と臨床への展開 がんと免疫,1版,2015年,p. 176-185
がん免疫療法のメカニズム解明と臨床への展開 がんと免疫,1版,2015年,p. 176-185
Attorney, Agent or Firm:
Go Akatsu